---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-023285"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2022-08-17T23:59:59+00:00"
generated_at: "2026-06-23T23:16:17.095489+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer

## Summary
- First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.
- Dose-escalation study to evaluate safety, maximum tolerated dose, and preliminary efficacy.
- Trial targets follicle stimulating hormone receptor (FSHR) on ovarian cells.
- Up to 48 patients may be enrolled in the study.
- CER-T approach differs from traditional CAR-T by targeting an endocrine receptor.

## SEC filing metadata
- accession: 0001493152-22-023285
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2022-08-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315222023285/0001493152-22-023285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315222023285/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-023285
- JSON: https://secwatch.observer/filing/0001493152-22-023285.json
- Plain text: https://secwatch.observer/filing/0001493152-22-023285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.